DelistingMay 27, 2026, 04:37 PM
Liminatus Pharma Faces Nasdaq Delisting; Files Appeal
AI Summary
Liminatus Pharma, Inc. received a notice from Nasdaq on May 20, 2026, stating that the company had not regained compliance with the $50 million market value of listed securities (MVLS) and $15 million market value of publicly held shares (MVPHS) requirements. Consequently, its securities will be delisted from The Nasdaq Global Market. The company has requested an appeal before the Nasdaq Hearings Panel on May 26, 2026, which will stay the delisting action pending the hearing.
Key Highlights
- Liminatus Pharma received notices on November 19, 2025, for non-compliance with Nasdaq's $50M MVLS and $15M MVPHS rules.
- The company had 180 calendar days, until May 18, 2026, to regain compliance.
- On May 20, 2026, Nasdaq notified the company of continued non-compliance, leading to delisting.
- Trading of Liminatus Pharma's securities will be suspended on May 29, 2026, unless an appeal is filed.
- Liminatus Pharma requested an appeal before the Nasdaq Hearings Panel on May 26, 2026.
- The appeal request will stay any suspension or delisting action pending the hearing.
Price Impact
More from LIMN